Skip to content


Blood Cancer Research

Cancer ResearchImmune Reconstitution in the Setting of Immunomodulatory Drug Maintenance Post-Allogeneic Stem Cell Transplantation (AlloSCT) in Myeloma (LenaRIC Study)

Treatment for myeloma can involve donor bone marrow transplants to provide patients with healthy blood cells. These help to attack tumour cells. However, It can take some time for the immune system to recover after the transplant. This leaves patients vulnerable to infections and cancer relapse. This project examined how well a new drug – Lenalidomie – helps to support the speed and quality of immune system recovery.

 

  • Principle investigator: Dr Gordon Cook and Dr Clive Carter
  • University of Leeds
  • Award amount: £51,900
  • April 2011 – March 2014

 

 

Cancer ResearchPim-1 chromatic modifier activity associated with myc-dependent gene expression

In cells, DNA is closely associated with a number of different proteins which help give it structure and stability. This complex of proteins and DNA is called chromatin. One way in which genes can be turned on and off is by rearranging the chromatin so that areas of DNA become exposed or hidden to certain molecules. PIM1 is a protein that affects chromatin structure, and is known to contribute to the development of aggressive lymphomas, and the major focus of this project was to determine how PIM1 helps to modify chromatin to promote cancer development.

 

  • Principle investigator: Dr Pascal Lefevre
  • University of Leeds
  • Award amount: £53,525
  • October 2011 – September 2014

 

 

Cancer ResearchChemokine receptor targeted cancer therapies “

CXCR4 is a receptor protein relevant to early cancer diagnosis, providing information on disease progression and potential treatment options. Researchers at the University of Hull have developed new compounds which bind to CXCR4 and have properties which suggest they may be more effective therapies than current drugs which target these receptors.

 

  • Principle investigator: Professor Stephen Archibald
  • University of Hull
  • Award amount: £123,312
  • March 2014 – February 2016

 

 

Cancer ResearchCombining reovirus with current treatment modalities to potentiate cytotoxic and immune-mediated CLL therapy

Chronic Lymphocytic Leukaemia (CLL) is a common form of adult leukaemia which remains incurable. Researchers at the University of Leeds are investigating how to improve survival by using an existing treatment – Rituximab – alongside an anti-cancer virus. Rituximab works by labelling cancer cells so the immune system can recognise and kill them. The virus in question – called reovirus- only grows in cancer cells, and can both 1) lead to the cancer cells’ death and 2) stimulate immune cells to kill the cancer. By combining these two approaches, the researchers may be able to increase the proportion of cancer cells eliminated by the immune system.

 

  • Principle investigator: Dr Fiona Errington-Mais
  • University of Leeds
  • Award amount: £197,087
  • September 2013 – August 2016

 

 

 
Cancer Types Icon
Information for researchers
Cancer Types Icon
Cancer Research Funded